GLP-3 RT
For laboratory research use only — not for human or animal consumption.
Research-grade retatrutide (GLP-3 RT), a 39-amino acid triple GIP/GLP-1/glucagon receptor agonist peptide, ≥99% HPLC purity with third-party batch-level Certificate of Analysis. For laboratory research use only.
Description
GLP-3 RT
GLP-3 RT is a synthetic 39-amino acid peptide and long-acting triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. Preclinical research examines its triple incretin/glucagon receptor pharmacology, energy expenditure, and metabolic endpoints in rodent and cell-based models.
Key Research Areas
- • Studied for concurrent agonism at GLP-1, GIP, and glucagon receptors for synergistic metabolic effects.
- • Investigated for energy-expenditure and body-composition endpoints in diet-induced obese rodent and hamster models.
- • Explored for improvements in glycemic control and lipid metabolism in obesity and type 2 diabetes research models.
Product Specifications
| Product | GLP-3 RT |
| CAS Number | 2381089-83-2 |
| Molecular Formula | C221H342N46O68 |
| Molar Mass | 4731.33 g/mol |
| Sequence | Modified lipidated 39-amino acid peptide (triple agonist analog) |
| Synonyms | GLP-3 RT; Reta LY3437943; triple agonist peptide |
| Purity | ≥99% (HPLC) |
| Form | Lyophilized powder |
| Storage | −20°C (−4°F) long-term; 2–8°C (36–46°F) reconstituted |
| Solubility | Bacteriostatic water for laboratory use |
Mechanism of Action
Retatrutide (LY3437943) is a single 39-amino acid peptide with a C20 fatty di-acid side chain that acts as an agonist at three receptors: GIP, GLP-1, and glucagon. In receptor assays it shows balanced GIP/glucagon activity with comparatively lower GLP-1 receptor potency. In diet-induced obese rodent and hamster models the glucagon-receptor component has been associated with increased energy expenditure and hepatic lipid effects, while the incretin components are associated with glucose homeostasis. These observations derive from in vitro assays and animal models; the material sold on this page has not been evaluated in controlled human trials.
Research Literature
- • Briand et al. (2026) — retatrutide metabolic endpoints in diet-induced obese MASH mouse and hamster models. PMID: 41741376.
- • Katsi et al. (2025) — review of retatrutide pharmacology as a GIP/GLP-1/glucagon triple agonist. PMID: 40563436.
- • Additional peer-reviewed literature is indexed on PubMed under the compound name.
Reconstitution & Storage
Lyophilized retatrutide is stable at −20°C or colder in its sealed vial; −80°C is preferable for long-term archival. Reconstitute in bacteriostatic water (0.9% benzyl alcohol) to a laboratory working concentration of 0.5–2 mg/mL for in vitro use. Once reconstituted, refrigerate at 2–8°C and use within approximately 30 days. Aliquot into single-use vials at reconstitution to avoid repeated freeze-thaw cycles of the working solution. Every batch ships with a third-party Certificate of Analysis; request the analytical file for your batch at /coa.
Research Use Only
For research use only. Not intended for human or veterinary consumption, therapeutic use, dietary supplementation, cosmetic use, or clinical application. Not FDA-approved. Purchasers confirm the material will be used solely for in vitro laboratory research and not administered to humans or animals.